urothelial cancer
Oncology · 2022–2022
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer. | Nov 2022 | Noted | none received |
What the PBS pays
$740M in government benefit over 2024–25, across 87,155 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nivolumabNivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | not recommended | 2018-07 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| cisplatinCISPLATIN ACCORD cisplatin 10 mg/10 mL concentrated injection vial | 1994 | 10 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.